A5080456032- Salivary Gland Tumors Diagnosis and Treatment
- Ear and Head Tumors
- Colorectal and Anal Carcinomas
- Nonmelanoma Skin Cancer Studies
- Immunotherapy and Immune Responses
- Head and Neck Cancer Studies
- Oral and Maxillofacial Pathology
- Sarcoma Diagnosis and Treatment
- Transplantation: Methods and Outcomes
- CAR-T cell therapy research
- Glioma Diagnosis and Treatment
- Head and Neck Anomalies
- Cancer Diagnosis and Treatment
- Head and Neck Surgical Oncology
The University of Texas MD Anderson Cancer Center
2023-2025
We conducted a phase II trial evaluating the efficacy of VEGFR inhibitor axitinib and PD-L1 avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
Adenoid cystic carcinoma (ACC) with NOTCH-activating mutations presents a clinical challenge due to its poor prognosis. NOTCH inhibitors have emerged as potential therapy for ACC patients activation. This study aimed evaluate the efficacy of in this patient population. A retrospective analysis was conducted on metastatic harboring pathway activation, who received at MD Anderson Cancer Center. included AL101, gamma-secretase inhibitor, and brontictuzumab, an antibody targeting NOTCH1....
6008 Background: Optimal treatment of larynx squamous cell carcinoma (LC) maximizes functional outcomes and survival. Surgery radiotherapy (RT) may lead to significant morbidity, notably dysphonia dysphagia. Our group published durable pathologic complete response (pCR) with normal function in 33% patients (pts) stage II-IV LC treated single modality chemotherapy. We hypothesized that pembrolizumab (P), cisplatin (C), docetaxel (D) will cure a subset pts preserve function. Methods: Eligible...
6111 Background: Despite aggressive local therapy, many ACC patients (~50%) develop recurrent and/or metastatic (R/M) disease. However, there is no standard of care or FDA-approved systemic therapy for this population. Based on small phase II trials, mostly including multiple salivary gland histologies, cytotoxic chemotherapy recommended symptomatic with high tumor burden, but its efficacy and impact survival in R/M remain unsubstantiated. Methods: A retrospective cohort study was conducted...